1. Federal University of Uberlândia, Brazil
Snake venom peptides: potential therapeutic agents in thrombotic diseases
Fábio de Oliveira, PhD
Federal University of Uberlândia, Brazil

2. Snake venom peptides: potential therapeutic agents in thrombotic diseases
BaltPAi: A heptapeptide platelet aggregation inhibitor from Bothrops alternatus snake venom
BmooPAF: a new platelet-activating factor from Bothrops moojeni snake venom
These works are in patenting process

3. Brazilian snakes genus
Bothrops Micrurus
Lachesis Crotalus

4. Snake Venom Snake venoms are rich sources of active toxins Venom
“Cocktail” of multiple active substances
Coagulation
Necrosis
Antiaggregation
Venom
pain
Edema
Proaggregation
Hemorrhage
Anticoagulauion
Bothrops moojeni (Caiçaca)
Purification only one toxin
Toxins from snake venom cause effect on platelet aggregation.

5. Purification of snake venom toxins
Venom extraction
Purification (Chromatography)
Lyophilized protein
Peptide synthesis
Isolation of venom toxins involves a complex sequence of chromatographic steps. The lyophilized preparation will remain active for many years

6. Human platelet

7. Platelet aggregation

8. BaltPAi: Purification
Ion-exchange
Reverse-phase HPLC
Molecular exclusion

9. BaltPAi: MALDI-TOF/TOF mass spectrometry analysis

10. BaltPAi: Platelet aggregation assays

11. Proposed mechanism of action of BaltPAi
BaltPAI acts as an antagonist of collagen receptors.

12. Myocardial infarction
Applications
BaltPai can be used in the prevention and treatment of vascular diseases such as:
Stroke
Thrombosis
Myocardial infarction

13. Conclusion
In this work, we first identified and synthesized one heptapeptide from B. alternatus snake venom with potent antiplatelet activity on collagen-induced platelet aggregation. This synthetic peptide can be of great importance to medicine since it has therapeutic potential for the development of antithrombotic drugs.

14. BmooPAF: Purification
Ion-exchange
Molecular exclusion

15. BmooPAF: MALDI-TOF/TOF mass spectrometry analysis

16. BmooPAF: Platelet aggregation assays
Anti-GP1BA (vWF)
Anti-GPVI (Collagen)
Anti-integrin α2b (Fibrinogen)
Collagen control
30 g
10 g

17. Proposed mechanism of action of BmooPAF
BaltPAI acts as a von Willebrand Factor agonist

18. Applications
BmooPAF can be used in the prevention and treatment of the von Willebrand's disease.
In addition, this synthetic peptide can also be used as a diagnostic tool for Bernard-Soulier Syndrome (bleeding disorder caused by a deficiency of GpIb).

19. Conclusion
In this work, we first identified and synthesized one decapeptide from B. moojeni snake venom that induces the platelet aggregation. This synthetic peptide can be of great importance to medicine since it has therapeutic potential for the development of antithrombotic drugs. This peptide can also be used as a new diagnostic tool for some platelet diseases.

20. Overall conclusion
These works describe the purification and characterization of new toxins from snake venom that interfere on platelet aggregation.
These toxins are divided into two classes: those that inhibit platelet aggregation and those that activate it. Both toxins are of medical interest, either as a tool for the development of new therapeutic agents to prevent and treat thrombotic disorders or as a tool for diagnosis

21. Thank you very much for your attention
Fábio de Oliveira, PhD
Federal University of Uberlândia